<p>William Blair 分析师 Lachlan Hanbury Brown 维持了对 LENZ 股票的看涨态度，并在 1 月 12 日给予了买入评级。</p>
<h3>在 TipRanks Premium 上享受 70% 折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
<p>Lachlan Hanbury Brown 给予买入评级的原因是与 LENZ Therapeutics 的商业进展和产品特征相关的多种因素。他认为，由 Sarah Jessica Parker 主导的 “Make it VIZZable” 直接面向消费者的宣传活动是提升品牌认知度和教育大量老花眼患者了解 VIZZ 的关键催化剂。该活动主要采用数字化策略，允许进行有针对性的推广和快速优化，他认为这应该会随着时间的推移转化为更高效的患者获取。他还将该活动在季度初的启动视为眼科专业人士已经开始接受该产品的证据，并且通过增加样品以满足预期需求得到了支持。</p>
<p>在更广泛的层面上，Hanbury Brown 强调 LENZ 现在已经稳步进入其商业阶段，VIZZ 的可用性被他视为公司一个重要的转折点。他认为 VIZZ 在临床特征上优于早期的老花眼治疗，特别是在有效性和效果持续时间方面，因此在一个尚未充分渗透的大市场中处于良好位置。尽管承认直接面向消费者的努力可能需要时间才能在处方中体现增长，但他认为强大的医生采纳、针对性的消费者营销和差异化产品的结合将支持有意义的长期收入增长。综合这些因素，他对风险回报的评估持积极态度，并为 LENZ 股票的买入推荐提供了依据。</p>
<p>Hanbury Brown 关注医疗保健行业，重点分析 Apellis Pharmaceuticals、LENZ Therapeutics 和 ARS Pharmaceuticals 等股票。根据 TipRanks 的数据，Hanbury Brown 的平均回报率为 24.6%，推荐股票的成功率为 60.00%。</p>
<p>在 1 月 12 日发布的另一份报告中，花旗也维持了对该股票的买入评级，目标价为 52.00 美元。</p>

LENZ

<p>威廉·布莱尔分析师拉赫兰·汉伯里·布朗对 LENZ Therapeutics 维持买入评级，原因是其商业进展和 “Make it VIZZable” 宣传活动的启动，该活动旨在教育老花眼患者。该活动的数字策略预计将增强患者获取。汉伯里·布朗将早期启动视为医生广泛采用的标志，并预计 LENZ 的差异化产品组合将带来显著的长期收入增长。花旗也支持这一观点，给予买入评级，并设定 52 美元的目标价</p>

<p>William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on LENZ stock, giving a Buy rating on January 12.</p>
<div class="lb-trans"><p>William Blair 分析师 Lachlan Hanbury Brown 维持了对 LENZ 股票的看涨态度，并在 1 月 12 日给予了买入评级。</p>
</div><h3>Claim 70% Off TipRanks Premium</h3>
<div class="lb-trans"><h3>在 TipRanks Premium 上享受 70% 折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
</div><p>Lachlan Hanbury Brown has given his Buy rating due to a combination of factors tied to LENZ Therapeutics’ commercial progress and product profile. He views the launch of the “Make it VIZZable” direct-to-consumer campaign, led by Sarah Jessica Parker, as a key catalyst to build brand recognition and educate the large population of presbyopic patients about VIZZ. The campaign’s predominantly digital strategy allows for targeted outreach and rapid optimization, which he believes should translate into more efficient patient acquisition over time. He also interprets the early-quarter start of this campaign, ahead of prior expectations, as evidence that eye care professionals are already embracing the product, supported by increased sampling to meet anticipated demand.</p>
<div class="lb-trans"><p>Lachlan Hanbury Brown 给予买入评级的原因是与 LENZ Therapeutics 的商业进展和产品特征相关的多种因素。他认为，由 Sarah Jessica Parker 主导的 “Make it VIZZable” 直接面向消费者的宣传活动是提升品牌认知度和教育大量老花眼患者了解 VIZZ 的关键催化剂。该活动主要采用数字化策略，允许进行有针对性的推广和快速优化，他认为这应该会随着时间的推移转化为更高效的患者获取。他还将该活动在季度初的启动视为眼科专业人士已经开始接受该产品的证据，并且通过增加样品以满足预期需求得到了支持。</p>
</div><p>At a broader level, Hanbury Brown highlights that LENZ is now firmly shifting into its commercial phase with VIZZ’s availability, which he regards as a significant inflection point for the company. He believes VIZZ offers a superior clinical profile versus earlier presbyopia treatments, particularly in terms of effectiveness and duration of benefit, and thus is well positioned in a large, underpenetrated market. While acknowledging that prescription growth from direct-to-consumer efforts may take time to show up in scripts, he sees the combination of strong physician adoption, targeted consumer marketing, and a differentiated product as supportive of meaningful long-term revenue growth. Collectively, these factors underpin his favorable risk-reward assessment and justify the Buy recommendation on LENZ shares.</p>
<div class="lb-trans"><p>在更广泛的层面上，Hanbury Brown 强调 LENZ 现在已经稳步进入其商业阶段，VIZZ 的可用性被他视为公司一个重要的转折点。他认为 VIZZ 在临床特征上优于早期的老花眼治疗，特别是在有效性和效果持续时间方面，因此在一个尚未充分渗透的大市场中处于良好位置。尽管承认直接面向消费者的努力可能需要时间才能在处方中体现增长，但他认为强大的医生采纳、针对性的消费者营销和差异化产品的结合将支持有意义的长期收入增长。综合这些因素，他对风险回报的评估持积极态度，并为 LENZ 股票的买入推荐提供了依据。</p>
</div><p>Hanbury Brown covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, LENZ Therapeutics, and ARS Pharmaceuticals. According to TipRanks, Hanbury Brown has an average return of 24.6% and a 60.00% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Hanbury Brown 关注医疗保健行业，重点分析 Apellis Pharmaceuticals、LENZ Therapeutics 和 ARS Pharmaceuticals 等股票。根据 TipRanks 的数据，Hanbury Brown 的平均回报率为 24.6%，推荐股票的成功率为 60.00%。</p>
</div><p>In another report released on January 12, Citi also maintained a Buy rating on the stock with a $52.00 price target.</p>
<div class="lb-trans"><p>在 1 月 12 日发布的另一份报告中，花旗也维持了对该股票的买入评级，目标价为 52.00 美元。</p>
</div>

LENZ Therapeutics：VIZZ 的早期发布、针对性的直接面向消费者活动以及差异化的老花眼特征支持买入评级